← Back to Home

Helping Therapeutic T Cells Evade One Inhibitor, Then Applying the Brakes with Another Drug

An Australian team used precise gene editing to help therapeutic T cells maintain their function in an immunosuppressive environment while retaining the possibility of drug-based control. Experiments with patient cells and mice have shown effects, but human use still requires validation.

By SURL BioNews

For patients who must continue receiving immunosuppressive treatment, cell therapy faces a dilemma: drugs that suppress harmful immune responses may also weaken T cells infused to treat disease. A team at Australia's Walter and Eliza Hall Institute of Medical Research (WEHI) is attempting to change this relationship, enabling therapeutic cells to evade suppression by a particular drug while retaining a control pathway through which another drug can intervene.

The study, presented by WEHI on October 20, was published online in *Blood* in July. According to the institute's announcement, the edited T cells resist tacrolimus but remain sensitive to cyclosporin. This means the researchers hope to allow therapeutic cells to keep working in the presence of one immunosuppressive drug, then reduce their activity with another drug if necessary; the evidence remains preclinical.

The approach uses multiplex prime editing to make precise changes in the cells' own genes, addressing disease-causing variants and drug resistance simultaneously. In a research seminar in September, the team called the platform CELECT. Its central idea is to use drugs commonly used in clinical practice to give corrected cells a relative advantage: when other, sensitive cells are suppressed, the therapeutic cells have an opportunity to expand selectively.

The researchers first tested this concept in patient cells. They corrected disease-causing HAVCR2 variants in T cells from multiple patients with subcutaneous panniculitis-like T-cell lymphoma while also introducing drug resistance. In humanized mouse models, these corrected cells were able to expand selectively under immunosuppressive pressure while retaining sensitivity to an alternative drug, allowing the researchers to suppress them again.

The team also extended the method to antigen-specific T cells and chimeric antigen receptor T cells (CAR-T), finding that the edited, drug-resistant cells retained immune effector function in a drug-suppressed environment. This offers a research direction for treatment settings in which immunosuppressants cannot be discontinued—for example, transplant recipients may need both to control rejection and to maintain the activity of therapeutic cells. However, the experiments have not demonstrated that patients can achieve better treatment outcomes as a result.

Safety analyses covered the genome, gene expression, immunophenotype and cell clonality, with the authors reporting limited unintended perturbations observed. This provides an important basis for advancing development, but is insufficient to rule out rare editing abnormalities or long-term risks. Whether drugs can reliably control the cells in humans, whether suppression is fast enough, and how different drug combinations affect the results all require further confirmation.

According to WEHI's announcement, the team is planning human testing. If the approach passes further validation, existing immunosuppressants could gain an additional use: alongside controlling patients' immune responses, they could help regulate therapeutic cells infused into the body. However, combining familiar drugs with newly edited cells still constitutes a new treatment combination whose safety and efficacy require independent evaluation.

References

  1. Walter and Eliza Hall Institute
  2. PubMed / Blood
  3. Peter MacCallum Cancer Centre Publications Repository
  4. Walter and Eliza Hall Institute